Skip to content

US · YDES

YD Bio Limited Ordinary Shares

Programmatic access: InvestorsCraft Valuation API · catalog

Sector
Healthcare · Biotechnology
Headquarters
Taipei, TP 115001

Price · as of 2026-09-03

$3.67

Market cap 159.37M

Price history

Weekly OHLC price history for YDES, USD per share
WeekOpenHighLowCloseVolume
Aug 4, 2025 – Aug 8, 2025$12.04$12.04$11.90$11.900
Aug 11, 2025 – Aug 12, 2025$12.00$12.15$12.00$12.100
Aug 18, 2025 – Aug 22, 2025$11.77$13.50$5.82$12.000
Aug 25, 2025 – Aug 29, 2025$12.00$16.50$5.30$12.500
Sep 1, 2025 – Sep 5, 2025$12.69$23.94$12.51$15.580
Sep 8, 2025 – Sep 12, 2025$15.50$25.00$15.30$23.110
Sep 15, 2025 – Sep 19, 2025$21.00$23.00$16.31$19.780
Sep 22, 2025 – Sep 26, 2025$18.25$21.50$12.90$16.000
Sep 29, 2025 – Oct 3, 2025$14.90$19.94$14.55$18.600
Oct 6, 2025 – Oct 10, 2025$18.34$19.49$17.00$17.410
Oct 13, 2025 – Oct 17, 2025$17.61$20.09$17.61$20.090
Oct 20, 2025 – Oct 24, 2025$20.39$22.00$17.15$17.190
Oct 27, 2025 – Oct 31, 2025$17.51$17.99$10.50$11.430
Nov 3, 2025 – Nov 7, 2025$11.60$11.98$8.47$8.990
Nov 10, 2025 – Nov 14, 2025$8.95$13.45$8.60$12.250
Nov 17, 2025 – Nov 21, 2025$12.19$12.70$7.98$8.450
Nov 24, 2025 – Nov 28, 2025$9.00$11.97$7.90$11.530
Dec 1, 2025 – Dec 5, 2025$11.50$14.88$10.90$13.910
Dec 8, 2025 – Dec 12, 2025$13.91$15.72$11.68$12.400
Dec 15, 2025 – Dec 19, 2025$12.55$13.40$11.00$12.380
Dec 22, 2025 – Dec 26, 2025$12.00$13.01$11.50$12.240
Dec 29, 2025 – Jan 2, 2026$12.25$12.53$11.67$12.000
Jan 5, 2026 – Jan 9, 2026$12.06$13.11$10.80$12.340
Jan 12, 2026 – Jan 16, 2026$12.00$12.32$11.30$11.320
Jan 19, 2026 – Jan 23, 2026$11.20$12.50$11.07$12.360
Jan 26, 2026 – Jan 30, 2026$12.39$12.39$11.03$11.870
Feb 2, 2026 – Feb 6, 2026$11.65$12.00$10.56$11.280
Feb 9, 2026 – Feb 13, 2026$11.54$11.80$9.76$9.840
Feb 16, 2026 – Feb 20, 2026$9.84$10.05$8.02$8.020
Feb 23, 2026 – Feb 27, 2026$8.03$9.46$8.00$8.580
Mar 2, 2026 – Mar 6, 2026$8.58$9.28$8.04$8.150
Mar 9, 2026 – Mar 13, 2026$8.09$8.39$7.30$7.300
Mar 16, 2026 – Mar 20, 2026$7.50$8.22$5.40$5.460
Mar 23, 2026 – Mar 27, 2026$5.41$8.77$5.41$7.810
Mar 30, 2026 – Apr 2, 2026$7.83$8.10$6.98$7.430
Apr 6, 2026 – Apr 10, 2026$7.79$7.79$5.70$6.260
Apr 13, 2026 – Apr 17, 2026$6.36$6.39$5.12$5.440
Apr 20, 2026 – Apr 24, 2026$5.57$6.00$5.00$5.460
Apr 27, 2026 – May 1, 2026$5.14$5.46$4.80$4.800
May 4, 2026 – May 8, 2026$4.73$5.37$4.73$5.310
May 11, 2026 – May 15, 2026$5.15$5.36$5.00$5.180
May 18, 2026 – May 22, 2026$5.06$5.28$4.37$4.750
May 25, 2026 – May 29, 2026$4.70$4.70$3.00$3.220
Jun 1, 2026 – Jun 5, 2026$3.01$3.90$2.88$3.010
Jun 8, 2026 – Jun 12, 2026$3.01$3.58$2.90$3.270
Jun 15, 2026 – Jun 18, 2026$3.26$3.39$2.38$2.420
Jun 22, 2026 – Jun 26, 2026$2.62$3.30$2.14$2.350
Jun 29, 2026 – Jul 2, 2026$2.32$2.97$1.70$1.900
Jul 6, 2026 – Jul 10, 2026$1.98$3.05$1.90$2.230
Jul 13, 2026 – Jul 17, 2026$2.15$2.50$1.99$2.450
Jul 20, 2026 – Jul 24, 2026$2.38$2.54$1.94$2.240
Jul 27, 2026 – Jul 31, 2026$2.21$2.60$2.10$2.170
Aug 3, 2026 – Aug 7, 2026$2.35$2.56$2.21$2.300
Aug 10, 2026 – Aug 14, 2026$2.28$3.24$2.17$2.980
Aug 17, 2026 – Aug 21, 2026$3.11$5.00$2.79$4.690
Aug 24, 2026 – Aug 28, 2026$4.66$4.85$3.09$4.800
Aug 31, 2026 – Sep 3, 2026$4.87$4.87$3.10$3.670

Valuation

MetricValueUpside
IC Value
P/E-58.60
P/B-170.56
P/S816.08
EV/EBITDA-59.36
PEG
P/TBV-89.12

Valuation history

Annual price overlaid with each model's fair value. Y-axis is log scale.

Annual price and model valuations for YDES, USD per share
YearPriceAIICGraham-DoddGraham Formula
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025$7.30

Historic valuation ratios

Pick a category, then toggle metrics to compare.

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About YD Bio Limited Ordinary Shares

        Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.

        CEO
        Ethan Shen
        Employees
        15
        Beta
        -0.12

        Peer comparison

        Same-industry comparables, ranked by market cap.

        Scroll horizontally for additional metrics. Ticker column stays fixed.

        Peer comparison for YDES: basic info, valuation models, ratios, profitability, leverage, growth, cash flow, dividends, enterprise value, and Altman Z-score.
        Basic InfoIC ValuationCore ValuationProfitabilityLeverage & LiquidityGrowthCash FlowDividendsEnterprise ValueRisk
        TickerCompany NamePriceMarket CapValueUpsideP/EP/BP/SEV/EBITDAPEGP/TBVGross MarginOperating MarginNet MarginROEROICROADebt/EquityInterest CoverageCurrent RatioQuick RatioNet Debt/EBITDAEPS GrowthSales GrowthFCF GrowthFCF YieldOp Cash Flow RatioCash ROICDividend YieldDividend PayoutShareholder YieldEV/EBITEV/FCFEV/SalesAltman Z-Score
        YDESYD Bio Limited Ordinary S…$2.30159.37M-58.60-170.56816.08-59.36-89.12-7.06%-883.31%-1392.61%-445.10%196.08%-80.52%0.005.884.090.74-78.57%16.94%69.27%-1.65%-4.01298.98%0.00%0.00%0.59%-91.25-59.86806.0216.01
        BTXBlackRock Innovation and …$8.52994.37M99.98%75.63%75.63%0.64%0.64%0.63%0.003452.510.130.13-0.05-100.00%-71.78%216.66%84.2865.02%1765.90%
        GERNGeron Corporation$1.631.05B$20.93+1,184%-12.284.665.73-18.204.6697.42%-29.28%-46.65%-33.89%-95.18%-14.74%1.11-1.654.663.58-3.32-51.85%138.83%-49.34%-10.55%-1.00-196.41%0.00%0.00%0.00%-17.56-8.515.14-1.85
        GLUEMonte Rosa Therapeutics, …$15.611.32B$24.11+54%-34.455.7110.76-31.655.7193.24%-43.83%-31.23%-16.94%49.88%-8.71%0.176.125.942.89-53.06%63.54%-172.35%-2.07%-0.3626.02%0.00%0.00%0.00%-18.32-36.118.032.97
        LENZLENZ Therapeutics, Inc.$5.27165.24M-4.261.2318.34-0.72-19.561.2396.31%-477.46%-430.25%-33.63%1694.33%-31.52%0.0014.2313.910.3021.79%16.94%-19.99%-3.261301.30%0.00%0.00%1.60%-0.64-0.843.078.89
        MRVIMaravai LifeSciences Hold…$6.41930.06M$46.68+628%-3.422.102.41-1.80-6.5117.98%-3.63%-70.41%-48.64%-3.22%-14.70%0.17-0.256.605.401.23-13.33%-28.34%218.67%-15.83%-1.28-34.44%0.00%0.00%52.73%-39.41-3.751.431.30
        PRMEPrime Medicine, Inc.$3.08556.3M$13.65+343%-2.704.49117.22-2.464.49-58.05%-4498.06%-4342.44%-146.81%-660.21%-62.83%0.964.844.74-0.27-18.26%55.28%28.38%-30.77%-4.34-529.49%0.00%0.00%0.00%-2.31-2.88104.00-3.65
        TBPHTheravance Biopharma Inc$16.90875.9M$395.66+2,241%6.552.346.453.302.3494.87%-12.33%98.54%44.85%-11.20%25.22%0.25-5.3810.9310.73-0.67-279.13%66.92%-2109.77%34.40%6.23246.03%0.00%0.00%15.63%-34.241.904.220.80
        TYRATyra Biosciences, Inc.$25.711.53B-18.008.33-15.98-54.358.330.00%0.00%0.00%-39.83%-1569.66%-37.13%0.0214.6714.150.6033.11%35.27%-4.41%-5.26-1126.54%0.00%0.00%0.00%-14.38-20.0352.94
        VIRVir Biotechnology, Inc.$9.111.54B$11.06+21%-2.931.6818.71-2.361.7382.92%-682.68%-638.87%-45.73%-112.47%-36.47%0.245.545.030.11-17.49%-7.61%-12.57%-30.92%-4.22-95.31%0.00%0.00%0.00%-2.15-2.5414.690.60

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $3.67) − 1 = — (IC, example).